Other studies showed similar encouraging results using TanCAR and nanobody-based bispecific CAR-T cell strategies, for example, combining targets against CD19 and CD20 [40], CD20 and HER2 [41], or CD22 and CD19 [42] for cancer treatment. The gene discussed is CD19; the disease is cancer.